MacroGenics Announces Interim Results for Lorigerlimab Cancer Trial

Key Facts

MacroGenics announced interim results for lorigerlimab in a clinical cancer trial. Investing.com reported that the company provided this scheduled update on its clinical pipeline to inform the medical community and investors about the progress of its oncology trials.

MGNX closed at $2.25 on October 23, 2026, with the stock trading between a low of $2.13 and a high of $3.57 during that session. These clinical results arrive as the company continues to develop specialized oncology treatments within the biotechnology sector.